DE69727399D1 - Verwendung von neutralen Gallium Chelaten mit 3-Hydroxy-4-Pyrone Verbindungen zur Behandlung von Krankheiten die verbessert werden Können durch die Hemmung der Hyperproliferation von Keratinocyten - Google Patents

Verwendung von neutralen Gallium Chelaten mit 3-Hydroxy-4-Pyrone Verbindungen zur Behandlung von Krankheiten die verbessert werden Können durch die Hemmung der Hyperproliferation von Keratinocyten

Info

Publication number
DE69727399D1
DE69727399D1 DE69727399T DE69727399T DE69727399D1 DE 69727399 D1 DE69727399 D1 DE 69727399D1 DE 69727399 T DE69727399 T DE 69727399T DE 69727399 T DE69727399 T DE 69727399T DE 69727399 D1 DE69727399 D1 DE 69727399D1
Authority
DE
Germany
Prior art keywords
hyperproliferation
keratinocytes
inhibiting
diseases
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69727399T
Other languages
English (en)
Other versions
DE69727399T2 (de
Inventor
Lawrence Richard Bernstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69727399D1 publication Critical patent/DE69727399D1/de
Application granted granted Critical
Publication of DE69727399T2 publication Critical patent/DE69727399T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69727399T 1996-07-30 1997-07-30 Verwendung von neutralen Gallium Chelaten mit 3-Hydroxy-4-Pyrone Verbindungen zur Behandlung von Krankheiten die verbessert werden Können durch die Hemmung der Hyperproliferation von Keratinocyten Expired - Lifetime DE69727399T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/688,565 US5747482A (en) 1996-07-30 1996-07-30 Methods and compositions to inhibit keratinocyte proliferation
US688565 1996-07-30
PCT/US1997/012951 WO1998004264A1 (en) 1996-07-30 1997-07-30 Methods and compositions to inhibit keratinocyte proliferation

Publications (2)

Publication Number Publication Date
DE69727399D1 true DE69727399D1 (de) 2004-03-04
DE69727399T2 DE69727399T2 (de) 2004-12-09

Family

ID=24764914

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69727399T Expired - Lifetime DE69727399T2 (de) 1996-07-30 1997-07-30 Verwendung von neutralen Gallium Chelaten mit 3-Hydroxy-4-Pyrone Verbindungen zur Behandlung von Krankheiten die verbessert werden Können durch die Hemmung der Hyperproliferation von Keratinocyten

Country Status (8)

Country Link
US (1) US5747482A (de)
EP (1) EP0959889B1 (de)
JP (1) JP2000516219A (de)
AT (1) ATE258440T1 (de)
AU (2) AU3726797A (de)
DE (1) DE69727399T2 (de)
ES (1) ES2214635T3 (de)
WO (2) WO1998004263A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203822B1 (en) * 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
DE60032915T2 (de) * 1999-10-04 2007-10-25 Bernstein, Lawrence Richard, Dr., Menlo Park Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen
US20020160055A1 (en) * 2000-09-18 2002-10-31 Jack Stapleton Methods for treating human immunodeficiency virus infections with gallium compositions
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
JP2003267966A (ja) * 2002-03-13 2003-09-25 Pola Chem Ind Inc フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤
US7081247B2 (en) * 2002-05-20 2006-07-25 Nidaria Technology Ltd. Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting
US7119217B2 (en) * 2002-09-23 2006-10-10 Genta Incorporated Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them
EP1993567A4 (de) * 2005-10-27 2011-01-26 Lawrence Richard Bernstein Oral verabreichbare gallium-zusammensetzungen und anwendungsverfahren
CN101484178A (zh) 2005-11-01 2009-07-15 赛德罗米克斯有限责任公司 使用镓化合物的口部和表面微生物的生长控制
CN101300033A (zh) * 2005-11-07 2008-11-05 泰坦医药品公司 用镓对不良肝脏病症的治疗和预防
EP1978976A2 (de) * 2006-01-30 2008-10-15 Titan Pharmaceuticals, Inc. Verwendung von gallium zur behandlung von biofilm-assoziierten infektionen
US8168214B2 (en) * 2006-11-09 2012-05-01 Bernstein Lawrence R Local administration of gallium compositions to treat pain
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
US20080175922A1 (en) * 2007-01-23 2008-07-24 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
WO2009009171A2 (en) * 2007-04-02 2009-01-15 Sideromics, Llc Methods for preventing or treating infectious diseases using gallium compounds
ES2336995B1 (es) * 2008-10-13 2011-02-09 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica para el cuidado de la piel,cuero cabelludo y uñas.
WO2016092493A1 (en) * 2014-12-12 2016-06-16 Glaxosmithkline Intellectual Property Development Limited Novel method of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2500303A1 (fr) * 1981-02-20 1982-08-27 Meram Lab Le chlorure de gallium, nouveau medicament anti-cancereux
DE3376387D1 (en) * 1982-10-22 1988-06-01 Sloan Kettering Inst Cancer The use of gallium salts for the manufacture of pharmaceutical compositions for the treatment of disorders of calcium homeostasis
US4704277A (en) * 1985-04-30 1987-11-03 Sloan-Kettering Institute For Cancer Research Methods of treating bone disorders
US5258376A (en) * 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
KR100196773B1 (ko) * 1990-01-12 1999-06-15 워얼렐 에스. 브로우;도날드 에스. 브로아즈 상처치유 및 조직회복을_향상시키기 위한 조성물
AU7981791A (en) * 1990-05-24 1991-12-10 Fujisawa, Inc. Orally administrable gallium compositions and methods of treatment therewith
US5175006A (en) * 1990-09-21 1992-12-29 The Ohio State University Method of treating arthritis using gallium compounds
JP3348849B2 (ja) * 1991-11-12 2002-11-20 ローレンス リチャード バーンスタイン ３−ヒドロキシ−４−ピロンのガリウム錯体の医薬組成物

Also Published As

Publication number Publication date
AU740198B2 (en) 2001-11-01
ES2214635T3 (es) 2004-09-16
ATE258440T1 (de) 2004-02-15
WO1998004264A1 (en) 1998-02-05
DE69727399T2 (de) 2004-12-09
WO1998004263A1 (en) 1998-02-05
JP2000516219A (ja) 2000-12-05
US5747482A (en) 1998-05-05
EP0959889B1 (de) 2004-01-28
AU3726797A (en) 1998-02-20
AU4044697A (en) 1998-02-20
EP0959889A1 (de) 1999-12-01
EP0959889A4 (de) 2000-08-16

Similar Documents

Publication Publication Date Title
DE69727399D1 (de) Verwendung von neutralen Gallium Chelaten mit 3-Hydroxy-4-Pyrone Verbindungen zur Behandlung von Krankheiten die verbessert werden Können durch die Hemmung der Hyperproliferation von Keratinocyten
ATE192652T1 (de) Zusammensetzung zur behandlung von preeclampsia und frühgeburt, die ein progestatives mittel und ein stickoxyd-synthäse substrat und/oder donor enthält
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE69512374D1 (de) Zusammensetzungen, die troxerutin als komplex mit phosphatidylcholin enthalten, zur topischen behandlung von erektionsimpotenz
DE60115000D1 (de) Die Verwendung von Prostaglandin F Analoga zur Herstellung von Zusammensetzungen für die Behandlung von Haarausfall.
MY101353A (en) Arylcarboxylic acid derivatives, the preparation and use thereof.
ATE342278T1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE247958T1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
DE69731477D1 (de) Mittel zur akne behandlung
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
ATE236643T1 (de) Verwendung von calendula-glykosiden zur behandlung der psoriasis
ATE272404T1 (de) Verwendung von taurolidine zur herstellung eines arzneimittels zur behandlung von leukämien
FR2451745A1 (fr) Procede de preparation d'immunoglobuline pour administration par voie intraveineuse
ATE183097T1 (de) Zusammensetzung und methode zur behandlung von störungen in form von depigmentierung
ATE75396T1 (de) Verwendung von kojic-saeure oder ihres betacyclodextrin-einschlusskomplexes zur praevention von elastosis.
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
DK227090A (da) Organisk guldkompleks til topisk anvendelse
DK0669834T3 (da) Anvendelse af topisk påført faktor Xlll til inhibering af blødning
ATE285778T1 (de) Topische verabreichung von bestimmten azapriranen zur vorbeugung oder behandlung von hautzuständen, die mit hautzellhyperproliferation und/oder immunologisch vermittelten krankheiten verbunden sind
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
FR2455610A1 (fr) Nouveaux steroides inhibiteurs de la 5a-reductase, utiles notamment pour le traitement de l'acne et leur procede de preparation
ATE227991T1 (de) Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
ATE209040T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen, die durch endothelzellen und fibrinogen ausgelöst werden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition